Crossmark

Targeting PVR (CD155) and its receptors in anti-tumor therapy

Crossref DOI link: https://doi.org/10.1038/s41423-018-0168-y

Published Online: 2018-10-01

Published Print: 2019-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kučan Brlić, Paola

Lenac Roviš, Tihana

Cinamon, Guy

Tsukerman, Pini

Mandelboim, Ofer

Jonjić, Stipan http://orcid.org/0000-0001-5003-3108
License Information

Text and Data Mining valid from 2018-10-01
More Information

Article History

Received: 13 July 2018

Accepted: 20 August 2018

First Online: 1 October 2018

Competing interests

: S.J., O.M. and P.T. are shareholders in Nectin Therapeutics Ltd. The remaining authors declare no competing interests.